Letrohexal

Letrozole, the active ingredient in Letrohexal, is an aromatase inhibitor presented as an oral tablet for systemic use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, both as adjuvant therapy and for advanced disease management.

GNH USA supplies Letrohexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global oncology treatment programs, including temperature‑controlled logistics where required.

Letrohexal, an aromatase inhibitor, is indicated for estrogen‑driven breast cancer conditions.

Hormone receptor‑positive breast cancer (postmenopausal): Reduces estrogen levels to inhibit tumor growth. Adjuvant treatment of early‑stage breast cancer (postmenopausal): Decreases risk of recurrence after surgery. Metastatic breast cancer (postmenopausal): Provides disease control in advanced settings.

Letrohexal may cause a range of adverse reactions. Patients should be monitored for any new or worsening symptoms.

Common Side Effects: - Hot flashes: Sudden feeling of warmth and sweating. - Joint and muscle pain: Arthralgia or myalgia affecting daily activities. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild to moderate upset stomach. - Headache: Tension‑type or throbbing pain. - Dizziness: Light‑headed sensation, especially when standing.

Serious or Rare Side Effects: - Severe liver injury: Jaundice, dark urine, or elevated liver enzymes. - Pulmonary embolism: Sudden shortness of breath, chest pain, or coughing up blood. - Bone fracture: Increased risk of osteoporosis‑related fractures. - Allergic reactions: Rash, itching, swelling, or anaphylaxis. - QT interval prolongation: Potential cardiac arrhythmias.

Before initiating Letrohexal, clinicians should evaluate patient history and monitor specific parameters.

Pregnancy avoidance: Contraindicated in pregnancy (Category X) due to teratogenic risk. Breastfeeding: Not recommended; letrozole may pass into breast milk. Bone health monitoring: Assess bone mineral density regularly and consider calcium/vitamin D supplementation. Cardiovascular risk: Monitor blood pressure and signs of thromboembolic events. Drug interactions: Review concomitant medications for CYP2A6 or CYP2C19 inhibitors. Store at ambient temperature: Keep below 25 °C, protect from moisture and light in the original container.

Letrohexal can interact with several medicines; careful review is essential.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors (e.g., ketoconazole): May increase letrozole plasma concentrations. - Concurrent tamoxifen therapy: Antagonistic effect on estrogen suppression. - Warfarin: Potentially heightened anticoagulant effect leading to bleeding.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine): May modestly raise letrozole levels. - Antacids containing aluminum or magnesium: May reduce oral absorption of letrozole. - Selective serotonin reuptake inhibitors (SSRIs): May influence bone metabolism and fracture risk.